JAMA Oncology : Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in ERBB2-Positive Breast Cancer
Interview with Thomas Hatschek, MD, PhD, author of Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - June 24, 2021 Category: General Medicine Authors: The JAMA Network Source Type: podcasts
Pembrolizumab, Trastuzumab, Capecitabine & Oxaliplatin In HER2+ mEGA
David Ilson, MD, PhD Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, Discusses Pembrolizumab, Trastuzumab, Capecitabine & Oxaliplatin...
Author: obr
Added: 02/06/2019 (Source: Oncology Tube)
Source: Oncology Tube - February 6, 2019 Category: Cancer & Oncology Source Type: podcasts
HER2 Mutation Positive NSCLC [720p]
Dr. Nathan Pennell, Cleveland Clinic, describes treatment of NSCLC patients with HER2 mutations using agents such as Gilotrif or Herceptin.
Author: cancergrace
Added: 10/11/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 11, 2018 Category: Cancer & Oncology Source Type: podcasts
the PERSEPHONE trial in early HER2+ breast cancer
Neelima Denduluri, MD, shares the results of the PERSEPHONE trial in early HER2+ breast cancer mean that 6 months of trastuzumab can be given rather than 12 months in the adjuvant setting
Author: obr
Added: 07/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 27, 2018 Category: Cancer & Oncology Source Type: podcasts
PERSEPHONE: 6 vs. 12-month adjuvant trastuzumab in early breast cancer
Trastuzumab has revolutionized the treatment of HER2+ breast cancer; however, the benefit of a longer duration of this therapy is uncertain. The PERSEPHONE trial (ISRCTN52968807) looked at the efficac...
Author: VJOncology
Added: 07/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 27, 2018 Category: Cancer & Oncology Source Type: podcasts
Trastuzumab-DKST has Regulatory Approval in US | 48-Week Survival & Safety of Monotherapy
Hope S. Rugo, MD, FASCO, University of California, San Francisco shares the Trastuzumab-DKST has Regulatory Approval in US | 48-Week Survival & Safety of Monotherapy at ASCO 2018
Author: Annual-Meeting
Added: 06/13/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 13, 2018 Category: Cancer & Oncology Source Type: podcasts
For Low-Level HER2 Breast Cancer, Trastuzumab Is a No-Go
Although the study didn ' t turn out as hoped, NSABP B-47 will help inform the decision of whether patients with low-level HER2 breast cancer should receive trastuzumab. (Source: Medscape Oncology)
Source: Medscape Oncology - December 29, 2017 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
Phase Ib Trial Evaluating T-DMI with Neratinib in Women with Metastatic HER2+ Breast Cancer
Jame Abraham, MD of Cleveland Clinic gives an overview of his abstract, NSABP FB-10: Phase Ib dose-escalation trial evaluating trastuzumab emtansine (T-DMI) with neratinib (N) in women with metastatic...
Author: aacr2017
Added: 04/18/2017 (Source: Oncology Tube)
Source: Oncology Tube - April 18, 2017 Category: Cancer & Oncology Source Type: podcasts
ONT-380 for HER2+ metastatic breast cancer: promising results for patients with brain metastases
Erika Hamilton of Sarah Cannon Research Institute, Nashville, TN talks about a Phase I trial of ONT-380 in combination with capecitabine and T-DM1 (trastuzumab emtansine), in patients with HER2+ metas...
Author: VJOncology
Added: 08/18/2016 (Source: Oncology Tube)
Source: Oncology Tube - August 18, 2016 Category: Cancer & Oncology Source Type: podcasts
JAMA Oncology : Neratinib vs Trastuzumab for Untreated Metastatic ERBB2-Positive Breast Cancer
Interview with Ahmad Awada, MD, PhD, author of Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial, and Mark D. Pegram, MD, author of Neratinib in ERBB2-Positive Brain Metastases (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - April 14, 2016 Category: Journals (General) Authors: The JAMA Network Source Type: podcasts
Neratinib vs Trastuzumab for Untreated Metastatic ERBB2-Positive Breast Cancer (JAMA Oncology)
Interview with Ahmad Awada, MD, PhD, author of Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial, and Mark D. Pegram, MD, author of Neratinib in ERBB2-Positive Brain Metastases (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - April 14, 2016 Category: Journals (General) Authors: The JAMA Network Source Type: podcasts
Abstracts from the 10th European Breast Cancer Conference: Lapatinib plus trastuzumab, male breast cancer, breast cancer registries
At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Fatima Cardoso, MD, from the Champalimaud Clinical Center, Lisbon, Portugal, provides...
Author: EMJ
Added: 03/31/2016 (Source: Oncology Tube)
Source: Oncology Tube - March 31, 2016 Category: Cancer & Oncology Source Type: podcasts
HER2 Mutation Positive NSCLC
Dr. Nathan Pennell, Cleveland Clinic, describes treatment of NSCLC patients with HER2 mutations using agents such as Gilotrif or Herceptin.
http://cancergrace.org/lung......
Author: cancergrace
Added: 02/22/2016 (Source: Oncology Tube)
Source: Oncology Tube - February 22, 2016 Category: Cancer & Oncology Source Type: podcasts
SABCS 2014: N9831 Trial Commentary by Dr. Edith Perez
Stromal tumor-infiltrating lymphocytes(S-TILs): In the alliance N9831 trial S-TILs are associated with chemotherapy benefit but not associated with trastuzumab benefit
Author: oncologyeducation
Added: 12/11/2014 (Source: Oncology Tube)
Source: Oncology Tube - December 12, 2014 Category: Cancer & Oncology Source Type: podcasts
Pertuzumab combined with trastuzumab plus chemotherapy adds approximately 16 months to median overall survival times for patients with HER2-positive metastatic breast cancer
At ESMO 2014, Prof Sandra Swain presents the results of a phase III trial (CLEOPATRA). The results show that patients with HER2-positive metastatic breast cancer treated with pertuzumab combined with ...
Author: EMJ
Added: 10/03/2014 (Source: Oncology Tube)
Source: Oncology Tube - October 3, 2014 Category: Cancer & Oncology Source Type: podcasts
